Introduction to Treating Patients with Buprenorphine for Primary Care Providers

8am-12pm

Click Here or Scan the QR Code to Register!

During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death, and providers that hold a DEA license with Schedule III Authority can prescribe Buprenorphine. Ensuring prescribers have the knowledge to initiate MOUD is imperative to helping patients with opioid use disorder.

Financial Incentive:

A $250 incentive will be provided to Primary Care Providers (Physicians and Advanced Practice Professionals) practice who attend this MOUD training. PCPs must also practice in Michigan and not have received an incentive for this training in the past. The incentive will be limited to the first 250 registered primary care providers, so please register early to ensure a spot.

4 CME Credits Pending (4.0 hours)

• Meets DEA Training Requirements

Learning Objectives:

• Understand the basics of the neurobiology of addiction
• Understand the basic pharmacodynamics of buprenorphine
• Describe the diagnosis, intake, and buprenorphine induction of a patient with OUD.
• Understand how to manage acute and chronic pain for patients with opioid use disorder with a specific emphasis on using buprenorphine for pain management
• Describe key principles in the outpatient management of patients with OUD

Presenters:

• Jonathan Morrow, MD, Ph.D
• Sheba Sethi, MD

Who should take this training:

• Physicians
• Nurse Practitioners
• Physician Assistants